Castle Biosciences Inc. (CSTL) Tops Q4 EPS by 22c

Castle Biosciences Inc. (NASDAQ: CSTL) reported Q4 EPS of ($0.25), $0.22 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $25 million versus the consensus estimate of $23.73 million.

GUIDANCE:

Castle Biosciences Inc. sees FY2022 revenue of $115-120 million.

For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.

You May Also Be Interested In

• McGraw Hill (MH) Tops Q2 EPS by 11c, Beats on Revenue; Offers FY26 Guidance
• Telesat Corporation (TSAT) Misses Q2 EPS by 1006c
• Legence Corp. (LGN) Misses Q2 EPS by 58c